Clinical trials: NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Ischemic Optic Neuropathy
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years.
- Trial name
- ENDOTHELION (NCT02377271)
- Testing
- bosentan
- Where
- 7 sites in France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Grenoble
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy
Patients diagnosed with NAION within 14 days of onset were included. Patients were randomized into 3 groups. Group 1 or control consisted of 30 patients who received gelatinous capsules filled with sugar as placebo.
- Trial name
- NAION (NCT02439866)
- Testing
- Intravenous methylprednisolone, normobaric oxygen with face mask
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma
Electric Stimulation of the Eye to Improve Vision After Trauma
Transcorneal Electrical Stimulation (TES) using the "OkuStim®" device delivers electrical impulses to damaged and/or diseased photoreceptor cells.
- Conditions
- Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
- Trial name
- TES (NCT02019927)
- Testing
- Transcorneal Electrical Stimulation
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Wills Eye
Non-arteritic Anterior Ischemic Optic Neuropathy
Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision.
- Trial name
- NCT00813059
- Testing
- Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Mount Sinai Hospital, Canada
Eye Diseases, Retinitis Pigmentosa
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT05147701
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Non Arteritic Anterior Ischemic Optic Neuropathy
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population.
- Trial name
- NCT02341560
- Testing
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg
- Where
- 85 sites in United States, Australia and 6 more
- Volunteers
- 732 people
- Sponsor
- Quark Pharmaceuticals
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Non-arteritic Ischemic Optic Neuropathy
Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
This series aims at studying the peripapillary and macular vascular changes in subjects with unilateral anterior ischemic optic neuropathy via Optical Coherence Tomography Angiography (OCTA).
- Trial name
- NCT06031350
- Testing
- Optical Coherence Tomography Angiography
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Omar Said
Non-arteritic Anterior Ischemic Optic Neuropathy
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Clinical trial.gov Brief summary : Non-arteritic anterior ischemic optic neuropathy (NAION) is an optic neuropathy due to acute or subacute ischemic event of anterior optic nerve axons retrolaminar part that was vascularized by…
- Trial name
- NAION (NCT03046693)
- Testing
- Group A Citicoline 1000 mg oral tablet
- Where
- Indonesia
- Volunteers
- 38 people
- Sponsor
- Valen Chia
Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy.
- Conditions
- Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy, Optic Neuropathy, Anterior Ischemic
- Trial name
- NCT01607671
- Testing
- Timolol maleate
- Where
- Canada
- Sponsor
- Fraser Health
Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy
Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve.
- Conditions
- Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
- Trial name
- VISION-GCA (NCT07206238)
- Testing
- Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION Treatment With Oral Prednisolone and Erythropoietin Injection
This randomized double-blind clinical trial is performed on all recent (within the last 5 days) NAION patients referred to hospitals affiliated to the Shahid Beheshti University of Medical Sciences, Iran.
- Trial name
- NAION (NCT03715881)
- Testing
- Oral prednisolone administration 50 mg, Intravenous Erythropoietin injection
- Where
- Iran
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the…
- Trial name
- NCT02045212
- Testing
- RPh201
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Regenera Pharma Ltd
Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
Clinical Study of FB1001 in Patients
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single/multiple intravitreal injection of FB1001 in patients with APACG(Acute Primary Angle-Closure…
- Conditions
- Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy, APAC - Acute Primary Angle Closure, Glaucoma, Angle-Closure
- Trial name
- NCT06506305
- Testing
- FB1001
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
- Trial name
- NCT01260324
- Testing
- No intervention given in this observational study
- Volunteers
- 21,283 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Non Arteritic Ischemic Optic Neuropathy
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
- Trial name
- Ampyra (NCT01975324)
- Testing
- dalfampridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neuro-Ophthalmologic Associates, PC
Non Arteritic Ischemic Optic Neuropathy
Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy
In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic…
- Trial name
- NEUROSTEM (NCT03173638)
- Testing
- intravitreal injection of MSV
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA